Cargando…

ARE STEM CELL MARKER EXPRESSION AND CD133 ANALYSIS RELEVANT TO DIFFERENTIATE COLORECTAL CANCER?

BACKGROUND: CD133 and AXL have been described as cancer stem cell markers, and c-MYC as a key regulatory cellular mechanism in colorectal cancer (CRC). AIM: Evaluate the prognostic role of the biomarkers CD133, AXL and c-MYC and their association with clinicopathologic characteristics in colorectal...

Descripción completa

Detalles Bibliográficos
Autores principales: CZECZKO, Leticia Elizabeth Augustin, RIBAS, Carmen Australia Paredes Marcondes, CZECZKO, Nicolau Gregori, SKARE, Thelma Larocca, YAMAKAWA, Camila Kienen, GIONEDIS, Guilherme, VASCONCELOS, Cecilia, BREMER, Fabiola Pabst, CASTOLDI, Diogo Francesco, GASSER, Martin, WAAGA-GASSER, Ana Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Colégio Brasileiro de Cirurgia Digestiva 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8521790/
https://www.ncbi.nlm.nih.gov/pubmed/34669880
http://dx.doi.org/10.1590/0102-672020210002e1585
_version_ 1784584958047682560
author CZECZKO, Leticia Elizabeth Augustin
RIBAS, Carmen Australia Paredes Marcondes
CZECZKO, Nicolau Gregori
SKARE, Thelma Larocca
YAMAKAWA, Camila Kienen
GIONEDIS, Guilherme
VASCONCELOS, Cecilia
BREMER, Fabiola Pabst
CASTOLDI, Diogo Francesco
GASSER, Martin
WAAGA-GASSER, Ana Maria
author_facet CZECZKO, Leticia Elizabeth Augustin
RIBAS, Carmen Australia Paredes Marcondes
CZECZKO, Nicolau Gregori
SKARE, Thelma Larocca
YAMAKAWA, Camila Kienen
GIONEDIS, Guilherme
VASCONCELOS, Cecilia
BREMER, Fabiola Pabst
CASTOLDI, Diogo Francesco
GASSER, Martin
WAAGA-GASSER, Ana Maria
author_sort CZECZKO, Leticia Elizabeth Augustin
collection PubMed
description BACKGROUND: CD133 and AXL have been described as cancer stem cell markers, and c-MYC as a key regulatory cellular mechanism in colorectal cancer (CRC). AIM: Evaluate the prognostic role of the biomarkers CD133, AXL and c-MYC and their association with clinicopathologic characteristics in colorectal adenocarcinomas and adenomas. METHODS: A total of 156 patients with UICC stage I-IV adenocarcinomas (n=122) and adenomas (n=34) were analyzed. Tissue microarrays (TMA) from primary tumors and polyps for CD133, c-MYC and AXL expression were performed and analyzed for their significance with clinicopathologic characteristics. RESULTS: Poorly differentiated adenocarcinomas and disease progression were independent risk factors for poor overall survival. The median overall survival time was 30 months. Positive CD133 expression (35.9% of all cases), particularly of right-sided CRCs (44.8% of the CD133+ cases), was negatively correlated with death in the univariate analysis, which did not reach significance in the multivariate analysis. c-MYC (15.4% of all cases) was predominantly expressed in advanced-stage patients with distant (non-pulmonary/non-hepatic) metastasis. AXL expression was found only occasionally, and predominantly dominated in adenomas, with less penetrance in high-grade dysplasia. CONCLUSIONS: CD133 expression was not associated with inferior overall survival in CRC. While AXL showed inconclusive results, c-MYC expression in primary CRCs was associated with distant metastasis.
format Online
Article
Text
id pubmed-8521790
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Colégio Brasileiro de Cirurgia Digestiva
record_format MEDLINE/PubMed
spelling pubmed-85217902021-10-27 ARE STEM CELL MARKER EXPRESSION AND CD133 ANALYSIS RELEVANT TO DIFFERENTIATE COLORECTAL CANCER? CZECZKO, Leticia Elizabeth Augustin RIBAS, Carmen Australia Paredes Marcondes CZECZKO, Nicolau Gregori SKARE, Thelma Larocca YAMAKAWA, Camila Kienen GIONEDIS, Guilherme VASCONCELOS, Cecilia BREMER, Fabiola Pabst CASTOLDI, Diogo Francesco GASSER, Martin WAAGA-GASSER, Ana Maria Arq Bras Cir Dig Original Article BACKGROUND: CD133 and AXL have been described as cancer stem cell markers, and c-MYC as a key regulatory cellular mechanism in colorectal cancer (CRC). AIM: Evaluate the prognostic role of the biomarkers CD133, AXL and c-MYC and their association with clinicopathologic characteristics in colorectal adenocarcinomas and adenomas. METHODS: A total of 156 patients with UICC stage I-IV adenocarcinomas (n=122) and adenomas (n=34) were analyzed. Tissue microarrays (TMA) from primary tumors and polyps for CD133, c-MYC and AXL expression were performed and analyzed for their significance with clinicopathologic characteristics. RESULTS: Poorly differentiated adenocarcinomas and disease progression were independent risk factors for poor overall survival. The median overall survival time was 30 months. Positive CD133 expression (35.9% of all cases), particularly of right-sided CRCs (44.8% of the CD133+ cases), was negatively correlated with death in the univariate analysis, which did not reach significance in the multivariate analysis. c-MYC (15.4% of all cases) was predominantly expressed in advanced-stage patients with distant (non-pulmonary/non-hepatic) metastasis. AXL expression was found only occasionally, and predominantly dominated in adenomas, with less penetrance in high-grade dysplasia. CONCLUSIONS: CD133 expression was not associated with inferior overall survival in CRC. While AXL showed inconclusive results, c-MYC expression in primary CRCs was associated with distant metastasis. Colégio Brasileiro de Cirurgia Digestiva 2021-10-18 /pmc/articles/PMC8521790/ /pubmed/34669880 http://dx.doi.org/10.1590/0102-672020210002e1585 Text en https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License
spellingShingle Original Article
CZECZKO, Leticia Elizabeth Augustin
RIBAS, Carmen Australia Paredes Marcondes
CZECZKO, Nicolau Gregori
SKARE, Thelma Larocca
YAMAKAWA, Camila Kienen
GIONEDIS, Guilherme
VASCONCELOS, Cecilia
BREMER, Fabiola Pabst
CASTOLDI, Diogo Francesco
GASSER, Martin
WAAGA-GASSER, Ana Maria
ARE STEM CELL MARKER EXPRESSION AND CD133 ANALYSIS RELEVANT TO DIFFERENTIATE COLORECTAL CANCER?
title ARE STEM CELL MARKER EXPRESSION AND CD133 ANALYSIS RELEVANT TO DIFFERENTIATE COLORECTAL CANCER?
title_full ARE STEM CELL MARKER EXPRESSION AND CD133 ANALYSIS RELEVANT TO DIFFERENTIATE COLORECTAL CANCER?
title_fullStr ARE STEM CELL MARKER EXPRESSION AND CD133 ANALYSIS RELEVANT TO DIFFERENTIATE COLORECTAL CANCER?
title_full_unstemmed ARE STEM CELL MARKER EXPRESSION AND CD133 ANALYSIS RELEVANT TO DIFFERENTIATE COLORECTAL CANCER?
title_short ARE STEM CELL MARKER EXPRESSION AND CD133 ANALYSIS RELEVANT TO DIFFERENTIATE COLORECTAL CANCER?
title_sort are stem cell marker expression and cd133 analysis relevant to differentiate colorectal cancer?
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8521790/
https://www.ncbi.nlm.nih.gov/pubmed/34669880
http://dx.doi.org/10.1590/0102-672020210002e1585
work_keys_str_mv AT czeczkoleticiaelizabethaugustin arestemcellmarkerexpressionandcd133analysisrelevanttodifferentiatecolorectalcancer
AT ribascarmenaustraliaparedesmarcondes arestemcellmarkerexpressionandcd133analysisrelevanttodifferentiatecolorectalcancer
AT czeczkonicolaugregori arestemcellmarkerexpressionandcd133analysisrelevanttodifferentiatecolorectalcancer
AT skarethelmalarocca arestemcellmarkerexpressionandcd133analysisrelevanttodifferentiatecolorectalcancer
AT yamakawacamilakienen arestemcellmarkerexpressionandcd133analysisrelevanttodifferentiatecolorectalcancer
AT gionedisguilherme arestemcellmarkerexpressionandcd133analysisrelevanttodifferentiatecolorectalcancer
AT vasconceloscecilia arestemcellmarkerexpressionandcd133analysisrelevanttodifferentiatecolorectalcancer
AT bremerfabiolapabst arestemcellmarkerexpressionandcd133analysisrelevanttodifferentiatecolorectalcancer
AT castoldidiogofrancesco arestemcellmarkerexpressionandcd133analysisrelevanttodifferentiatecolorectalcancer
AT gassermartin arestemcellmarkerexpressionandcd133analysisrelevanttodifferentiatecolorectalcancer
AT waagagasseranamaria arestemcellmarkerexpressionandcd133analysisrelevanttodifferentiatecolorectalcancer